Experts offer advice on treating patients with belantamab mafodotin-based combinations in myeloma

This video is part of a series of videos on the DREAMM studies.

In this discussion, the panel provides advice to community physicians on using belantamab mafodotin-based combinations in relapsed or refractory multiple myeloma, including dosing strategies and managing toxicities while maintaining efficacy.

The panel features Dr. Saad Usmani, chief of myeloma service at Memorial Sloan Kettering Cancer Center, along with panelists Dr. Meletios A. Dimopoulos, professor and chairman of the department of clinical therapeutics at the National and Kapodistrian University of Athens School of Medicine, Dr. Hans Lee, director of myeloma research at the Sarah Cannon Research Institute, and Dr. Ajay Nooka, clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.

Discussing the broader landscape of global myeloma care and the realities of patient access and preferences, Dr. Lee emphasized the need for personalized approaches.

“One size doesn’t fit all for our patient populations,” Dr. Lee said.

Watch the rest of the conversation here.